REVIA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Revia, and what generic alternatives are available?
Revia is a drug marketed by Teva Womens and is included in one NDA.
The generic ingredient in REVIA is naltrexone hydrochloride. There are nineteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the naltrexone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Revia
A generic version of REVIA was approved as naltrexone hydrochloride by BARR on May 8th, 1998.
Summary for REVIA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 46 |
Patent Applications: | 8,524 |
Formulation / Manufacturing: | see details |
DailyMed Link: | REVIA at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for REVIA
US Patents and Regulatory Information for REVIA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Womens | REVIA | naltrexone hydrochloride | TABLET;ORAL | 018932-001 | Nov 20, 1984 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |